Novartis has a Nephrology pipeline base on Iptacopan, and one target therapy is lgAN. As a result, Iptacopan is one future potential Nefecon challenger. During the ongoing ERA-ERDTA Congress, Novartis presented top-line phase II results based on 112 patients after 90 days.